The effect of immune modulation platform for influenza treatment investigated with a platform trial (Imprint Trial)

Efficacy of Immune Modulatory Treatment for Severe Influenza: The Randomized Embedded Multifactorial Adaptive Platform Trial For Community Acquired Pneumonia (Remap-Cap) Influenza Immune Modulation Domain (Imprint Trial) There are no proven effective treatments for patients who are admitted to Intensive Care (IC) with pneumonia by the influenza virus (flu). The inflammatory reaction that arises in these patients is very similar to the "hyperinflammation" reaction that was also seen in seriously ill patients with COVID-19. Study and expected outcomes Because of this comparable "hyperinflammation" response, the Imprint study will investigate whether treatments with Tocilizumab and Baricitinib, who have proven to be effective for seriously ill patients with COVID-19, also being effective in severe pneumonia with the influenza virus. The expectation is to prevent disease and death, to prevent the virus spread and reduce the pressure on scarce IC beds. Even if a new pandemic was created by the influenza virus, it is important to know whether these resources work. The study takes place in collaboration with international researchers from the Remap-Cap Study, which played an important role in finding effective treatments against the coronavirus. The result is the patient situation 90 and 180 days after admission to the IC. More information Study into new treatment of severe pneumonia due to the flu (April 2024, UMC Utrecht)